EP2714080A4 - Methods of treating systemic lupus erythematosus, scleroderma, and myositis with an antibody against interferon-alpha - Google Patents

Methods of treating systemic lupus erythematosus, scleroderma, and myositis with an antibody against interferon-alpha

Info

Publication number
EP2714080A4
EP2714080A4 EP12789521.7A EP12789521A EP2714080A4 EP 2714080 A4 EP2714080 A4 EP 2714080A4 EP 12789521 A EP12789521 A EP 12789521A EP 2714080 A4 EP2714080 A4 EP 2714080A4
Authority
EP
European Patent Office
Prior art keywords
myositis
scleroderma
alpha
methods
lupus erythematosus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP12789521.7A
Other languages
German (de)
French (fr)
Other versions
EP2714080A1 (en
Inventor
Ryan Criste
Lorin Roskos
Wendy White
Dominique Ethgen
Rajesh Narwal
Gabriel Robbie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune LLC filed Critical MedImmune LLC
Publication of EP2714080A1 publication Critical patent/EP2714080A1/en
Publication of EP2714080A4 publication Critical patent/EP2714080A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP12789521.7A 2011-05-25 2012-05-23 Methods of treating systemic lupus erythematosus, scleroderma, and myositis with an antibody against interferon-alpha Withdrawn EP2714080A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161489949P 2011-05-25 2011-05-25
PCT/US2012/039098 WO2012162367A1 (en) 2011-05-25 2012-05-23 Methods of treating systemic lupus erythematosus, scleroderma, and myositis with an antibody against interferon-alpha

Publications (2)

Publication Number Publication Date
EP2714080A1 EP2714080A1 (en) 2014-04-09
EP2714080A4 true EP2714080A4 (en) 2014-11-19

Family

ID=47217695

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12789521.7A Withdrawn EP2714080A4 (en) 2011-05-25 2012-05-23 Methods of treating systemic lupus erythematosus, scleroderma, and myositis with an antibody against interferon-alpha

Country Status (9)

Country Link
EP (1) EP2714080A4 (en)
JP (1) JP2014516970A (en)
KR (1) KR20140043402A (en)
CN (1) CN103732251A (en)
BR (1) BR112013030242A2 (en)
CA (1) CA2836926A1 (en)
MX (1) MX2013013785A (en)
RU (1) RU2013157177A (en)
WO (1) WO2012162367A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2791170A1 (en) 2011-12-16 2014-10-22 Synthon Biopharmaceuticals B.V. Compounds and methods for treating inflammatory diseases
WO2013101771A2 (en) * 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
ES2745103T3 (en) * 2013-06-15 2020-02-27 Tocagen Inc Gammaretrovirus-based virus-like immunosuppressive particles
CN103740755A (en) * 2013-12-23 2014-04-23 中国农业大学 Application of IFIT1 gene of pig in resisting PRRS (porcine reproductive and respiratory syndrome) virus
RU2580301C1 (en) * 2015-04-21 2016-04-10 Людмила Николаевна Хон Method for treatment of human systemic lupus erythematosus
CN107058521B (en) * 2017-03-17 2019-12-27 中国科学院北京基因组研究所 Detection system for detecting human body immunity state
EP3853859A1 (en) * 2018-10-11 2021-07-28 Vivia Biotech, S.L. A method for determining the efficacy of treatment with a combination of drugs in a subject diagnosed with a disease and a method for classifying the utility of drug combinations in treatment of said subject
JP2022512796A (en) 2018-10-26 2022-02-07 ヤンセン バイオテツク，インコーポレーテツド Type I interferon signature and methods of use
JP2022527542A (en) * 2019-04-04 2022-06-02 ヤンセン バイオテツク，インコーポレーテツド Anti-IFN-α / ω antibody administration method
AU2023335547A1 (en) 2022-08-29 2025-02-27 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Method for screening and preparing immunomodulator
KR20250057823A (en) 2022-08-29 2025-04-29 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 Fusion proteins comprising TACI polypeptides and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009061818A1 (en) * 2007-11-05 2009-05-14 Medimmune, Llc Methods of treating scleroderma
WO2009135861A2 (en) * 2008-05-07 2009-11-12 Novo Nordisk A/S Humanized antibodies against human interferon-alpha
WO2010042705A1 (en) * 2008-10-09 2010-04-15 Medimmune, Llc Antibody formulation
WO2012149228A1 (en) * 2011-04-26 2012-11-01 Genentech, Inc. Compositions and method for treating autoimmune diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7087726B2 (en) * 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
KR101225299B1 (en) * 2003-12-10 2013-01-24 메다렉스, 인코포레이티드 Interferon alpha antibodies and their uses
KR20080025174A (en) * 2005-06-23 2008-03-19 메디뮨 인코포레이티드 Antibody Preparations with Optimized Aggregation and Fragmentation Profiles

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009061818A1 (en) * 2007-11-05 2009-05-14 Medimmune, Llc Methods of treating scleroderma
WO2009135861A2 (en) * 2008-05-07 2009-11-12 Novo Nordisk A/S Humanized antibodies against human interferon-alpha
WO2010042705A1 (en) * 2008-10-09 2010-04-15 Medimmune, Llc Antibody formulation
WO2012149228A1 (en) * 2011-04-26 2012-11-01 Genentech, Inc. Compositions and method for treating autoimmune diseases

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HIGGS BRANDON W ET AL: "IFN-alpha/beta as a therapeutic target in SLE, myositis, and RA: A transcript profiling analysis of whole blood from several autoimmune diseases", ARTHRITIS & RHEUMATISM, WILEY, US, vol. 58, no. 9, Suppl. S, 1 September 2008 (2008-09-01), pages S667 - S668, XP009147410, ISSN: 0004-3591 *
MCBRIDE ET AL: "Dose-Dependent Modulation of Interferon Regulated Genes with Administration of Single and Repeat Doses of Rontalizumab in a Phase I, Placebo Controlled, Double Blind, Dose Escalation Study in SLE", INTERNET CITATION, 2009, pages 2072, XP002697717, ISSN: 0004-3591, Retrieved from the Internet <URL:http://www.blackwellpublishing.com/acrmeeting/abstract.asp?MeetingID=761&id=81694> [retrieved on 20130527] *
RONAN J WALSH ET AL: "Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis", ARTHRITIS & RHEUMATISM, WILEY, US, vol. 56, no. 11, 1 November 2007 (2007-11-01), pages 3784 - 3792, XP008127186, ISSN: 0004-3591, DOI: 10.1002/ART.22928 *
See also references of WO2012162367A1 *
YAO Y ET AL: "Neutralization of interferon-[alpha]/[beta]-inducible genes and downstream effect in a phase I trial of an anti-interferon-[alpha] monoclonal antibody in systemic lupus erythematosus", ARTHRITIS & RHEUMATISM, WILEY, US, vol. 60, no. 6, 1 June 2009 (2009-06-01), pages 1785 - 1796, XP009147413, ISSN: 0004-3591, [retrieved on 20090528], DOI: 10.1002/ART.24557 *

Also Published As

Publication number Publication date
WO2012162367A1 (en) 2012-11-29
MX2013013785A (en) 2014-07-28
JP2014516970A (en) 2014-07-17
CN103732251A (en) 2014-04-16
EP2714080A1 (en) 2014-04-09
BR112013030242A2 (en) 2016-12-06
KR20140043402A (en) 2014-04-09
RU2013157177A (en) 2015-06-27
CA2836926A1 (en) 2012-11-29

Similar Documents

Publication Publication Date Title
EP2714080A4 (en) Methods of treating systemic lupus erythematosus, scleroderma, and myositis with an antibody against interferon-alpha
GB2515195B (en) Improved fuel cell systems and methods
TWI563717B (en) Fuel cell stack assembly and method of assembly
GB2491982B (en) Aircraft power systems and methods
PT2925782T (en) Anti-cd47 antibodies and methods of use thereof
EP3079719B8 (en) Anti-siglec-8 antibodies and methods of use thereof
SI2668683T1 (en) An improved battery and assembly method
AP2014007502A0 (en) Systems and methods for diagnosting an engine
IL235418A0 (en) Biological active bullets, systems, and methods
EP3060253A4 (en) ANTI-Ly6E ANTIBODIES AND METHODS OF USE
IL216475A (en) Navigation system and method with location-aware accuracy and/or power adjustments
EP3063989A4 (en) Methods and arrangements for optimized scheduled delivery
EP2953233A4 (en) Multi-battery charger and control method therefor
EP2997166A4 (en) Analyte enrichment methods and compositions
GB201319966D0 (en) Fuel cell assembly and method
EP3082137A4 (en) Compression-bonded magnet with case, and method for producing same
EP3007733A4 (en) Fixed and portable coating apparatuses and methods
SG11201600932XA (en) Methods, apparatuses, and systems for cell and tissue culture
EP3542584A4 (en) Methods and apparatuses for subframe scheduling
EP3060580A4 (en) Anti-podocalyxin antibodies and methods of using the same
EP3060924A4 (en) Pif-transfected cells and methods of use
EP3077510A4 (en) Antisense compounds and uses thereof
EP2970900A4 (en) Compounds for inducing proliferation and differentiation of cells, and methods of use thereof
EP3027859A4 (en) Systems, methods, and apparatuses related to vehicles with reduced emissions
GB2489105C (en) Processing an embedded metal film, and component with an embedded metal film

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20131220

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20141017

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/28 20060101ALI20141013BHEP

Ipc: A61K 39/00 20060101ALI20141013BHEP

Ipc: A61K 39/395 20060101AFI20141013BHEP

Ipc: C07K 16/42 20060101ALI20141013BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150516